In-depth Cost Analyses Uncover Surprising Facts about Enrollment Efficiency
Expired and expiring patents for dozens of products are forcing the clinical research-based industry to streamline and quicken R&D. Yet, even as stakes for company R&D are intensifying, our stifling climate of risk aversion has decision makers falling back on the customary, rather than advocating for the exceptional. Unfortunately, this is the case even when it means passing up on a chance to gain real efficiencies in patient enrollment and retention, the most costly aspect of the clinical trial process.
We all know that over 80 percent of all clinical trials are now delayed up to six months due to enrollment and retention issues. The consequences are missed milestones, wasted patent exclusivity, and significant cost overruns, which in today’s climate are unforgiving. Clinical trial protocols are increasingly complex with more procedures, longer case report forms, and longer consent forms burdening clinical trial staff and patients alike. Regulators are requiring more clinical trials per compound, more patients for each clinical trial, and more follow-up data on patients, whether they complete the study or not.
So how do drug companies begin to streamline R&D in this contentious environment? (Hint: It’s not social media, everyone’s favorite strategy of hope.) It’s by taking another look at solutions that really work. This session will examine the true value of patient recruitment and offer cost analyses uncovering surprising facts about enrollment efficiency.
Presented by
Richard Malcolm, PhD,
Executive Vice President & General Manager, Acurian
Rick brings over 28 years experience in healthcare management to Acurian. Prior to that, Rick was VP, Business Development, for ICON Clinical Research, one of the world's largest CROs. Rick started his career at SmithKline Beecham (now GSK) in product marketing for cardiovascular, gastrointestinal, depression & anti-arthritic products. Also, he was worldwide head for their Clinical Trials Center (now Quest's central lab), and in senior management and consulting roles at start-up pharmaceuticals.
